RefleXion is the first and only company to develop SCINTIX® therapy, a novel radiotherapy that uses biological signals—specifically PET emissions from cancer cells—to direct external-beam radiation delivery in real time. This innovation combines the precision of molecular targeting with the effectiveness of radiotherapy for treating lung and bone tumors that arise from primary or metastatic cancers.
An
oral scientific session highlighting SCINTIX therapy entitled “Realtime PET guided External Beam Radiation Therapy: Initial Experience” will be held on Mon., June 23 at 10:50AM in Convention Center 210.
To date, RefleXion has successfully delivered over 350 SCINTIX therapy procedures via the RefleXion® X1 platform, marking rising clinical adoption.
Ad Statistics
Times Displayed: 2839
Times Visited: 27 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
SCINTIX therapy transforms diagnostic PET tracers into real-time treatment bioguides, creating a new utility and market in nuclear medicine. Currently cleared for use with FDG to treat lung or bone tumors, RefleXion is investigating a portfolio of tracers, including PSMA-targeted agents for treating prostate cancer, and a proprietary FAP tracer with pan-cancer applications.
Visit us at booth 1142 during SNMMI 2025. Learn more at
www.reflexion.com or contact
[email protected].
